



PRESS RELEASE

SUBLIMED obtains the CE mark for its transcutaneous electrical nerve stimulator, actiTENS

This key milestone allows SUBLIMED to begin marketing its medical device actiTENS in France for treating patients with chronic pain.

Grenoble, February 14, 2018 – [SUBLIMED](#), a company specializing in the development of non-drug solutions for treating patients with chronic pain, today announced that it has obtained the CE mark for its Class IIa medical device actiTENS and its smartphone application for managing it and collecting patient monitoring data.

This regulatory approval means that the actiTENS device can now be marketed in Europe. The product is available for sale or by prescription in France from today.

"We are proud to have obtained the CE mark for actiTENS after two years of hard work by the SUBLIMED team," said Nicolas Karst, co-founder and CEO of SUBLIMED. "This represents a crucial step in the development of the company. The actiTENS device is available by prescription at 250 French pain centers ahead of an international roll-out. A new fund raising campaign is planned for 2018 to support this objective. "

SUBLIMED has also just received the ISO 13485 certification for its quality management system, issued by the BSI notified body.

A new approach to treating chronic pain

Founded in October 2015 by Nicolas Karst, CEA engineer, and Dr. Jean-Pierre Alibeu, former department head of the Pain Center at CHU Grenoble [Grenoble University Hospital Center], SUBLIMED aims to revolutionize the treatment of chronic pain.

The company's first product, actiTENS, is based on a non-drug therapy, transcutaneous electrical nerve stimulation (TENS). actiTENS is also the first TENS device which discreetly helps the patient in their day-to-day activities and provides them with pain relief in all situations.

actiTENS comes in the form of a miniature, flexible box that can be placed directly on the body and controlled wirelessly by a smartphone using a dedicated app. This application, developed by SUBLIMED, also enables health professionals to monitor treatment.

About Sublimed

Created in October 2015, SUBLIMED develops innovative solutions for treating chronic pain. A spin-off of CEA, SUBLIMED has an exclusive and global operating license agreement covering a portfolio of patents protecting the actiTENS device. This transcutaneous electrical nerve stimulation (TENS) device helps to provide chronic pain relief for the patient and discreetly helps them in their day-to-day activities.

SUBLIMED raised more than €700,000 in 2016 and won several innovation competitions and awards.

More information: <http://subli-med.fr/>

Press contact

Mahoney Lyle

Céline Gonzalez

cgonzalez@mahoneylyle.co

[m +33 6 75 85 60 42](tel:+33675856042)

Sublimed Contact

Nicolas Karst, CEO

nicolas.karst@subli-med.com